RxDoctor Payments Data

Youstina Bolos, DPM

Podiatrist · Brandon, FLNPI 1073976429

Payments from drug & device makers

$5,029in general payments, 2019–2025

Across 42 payments — averaging $119.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • MVP Orthopedics Inc$2K
  • Stryker$996
  • Kerecis Limited$342
  • Sanara Medtech Inc.$209
  • Coastal Medical Technologies LLC$184
  • Smith+Nephew$180
  • plus $1K from 16 others

What the payments were for

  • Food & beverage$3,26165%
  • Education$1,76835%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
MVP Orthopedics Inc1$1,768
Stryker7$996
Kerecis Limited3$342
Sanara Medtech Inc.1$209
Coastal Medical Technologies LLC2$184
Smith+Nephew6$180
Zynex Medical, Inc.1$170
Paratek Pharmaceuticals, Inc.3$159
Linvatec Corporation1$150
Bone Support Inc.1$144
Medline Industries LP1$140
Orpyx Medical Technologies US Inc.1$108
Trice Medical, Inc.2$98
Hydrocision, Inc.1$76
Triad Life Sciences Inc.1$66
Bioventus LLC2$55
Organogenesis Inc.2$52
Medtronic2$47
Next Science LLC1$31
Curonix LLC1$22
SPR Therapeutics, Inc1$16
Averitas Pharma Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,029 in reported general payments places this provider in the 80th percentile of 588 podiatrist providers in Florida.

See all podiatrist providers in Florida

Medicare billing

Part B allowed, 2024
$233,666
Medicare patients
477
Services billed
2,472

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
SantylCollagenase Clostridium Hist.13$6,593
Ciclopirox45$1,539
Gabapentin44$281
Methylprednisolone33$238
Doxycycline Hyclate27$237
Mupirocin30$226
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim29$193
Meloxicam53$142
Clotrimazole25$101
Silver Sulfadiazine17$81

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Smith+NephewSantyl$180$6,59313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 588 podiatrist providers in Florida.

Other podiatrist in Brandon

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →